Literature DB >> 12042264

Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women.

Elof Johansson1, Vivian Brache, Frank Alvarez, Anibal Faundes, Leila Cochon, Sirpa Ranta, Mark Lovern, Narender Kumar.   

Abstract

BACKGROUND: Levonorgestrel (LNG) is a commonly used progestin for emergency contraception; however, little is known about its pharmacokinetics and optimal dose for use.
METHODS: Serum levels of LNG and sex hormone-binding globulin (SHBG) were measured in five women who received three different regimens: A: 0.75 mg LNG twice with a 12 h interval; B: 0.75 mg twice with a 24 h interval; and C: 1.50 mg in a single dose, with a washout period of 28 days between each treatment. Blood samples were taken before pill intake and at 1, 2, 4, 8 and 12 h after each dose, every 12 h up to day 4 and every 24 h until day 10. LNG and SHBG were measured in all samples.
RESULTS: Maximum LNG concentrations were of approximately 27 nmol/l for treatments A and B, and close to 40 nmol/l for treatment C. The area under the curve was significantly higher for treatment C during the first 12 h, and significantly lower for treatment B during the first 24 h. After 48 h and up to 9 days from onset of treatment, serum LNG levels were similar in all three regimens. SHBG levels remained stable for 24 h, decreasing to 60% of the initial value from day 5 until day 10, with no difference between regimens.
CONCLUSIONS: The similarity of LNG serum levels obtained with one single dose of 1.5 mg or two doses of 0.75 mg with a 12 h interval justify a clinical comparison of these two regimes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042264     DOI: 10.1093/humrep/17.6.1472

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  10 in total

1.  Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception.

Authors:  Regine Sitruk-Ware; Vivian Brache; Robin Maguire; Horacio Croxatto; Narender Kumar; Sushma Kumar; Juan Carlos Montero; Ana Maria Salvatierra; David Phillips; Anibal Faundes
Journal:  Contraception       Date:  2007-04-18       Impact factor: 3.375

2.  Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity: A Randomized Controlled Trial.

Authors:  Alison B Edelman; Jon D Hennebold; Kise Bond; Jeong Y Lim; Ganesh Cherala; David F Archer; Jeffrey T Jensen
Journal:  Obstet Gynecol       Date:  2022-06-07       Impact factor: 7.623

3.  Effect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for "dual protection" emergency contraception.

Authors:  Vivian Brache; Horacio Croxatto; Regine Sitruk-Ware; Robin Maguire; Juan Carlos Montero; Narender Kumar; Ana Maria Salvatierra; Ana Sofia Tejada; Leila Cochón; María Luisa Forcelledo; Pekka Lahteenmaki; Francisco Alvarez; Anibal Faundes
Journal:  Contraception       Date:  2007-06-13       Impact factor: 3.375

4.  A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception.

Authors:  YongMei Huang; Jeffrey T Jensen; Vivian Brache; Leila Cochon; Alistair Williams; Maria-José Miranda; Horacio Croxatto; Narender Kumar; Heather Sussman; Elena Hoskin; Marlena Plagianos; Kevin Roberts; Ruth Merkatz; Diana Blithe; Regine Sitruk-Ware
Journal:  Contraception       Date:  2014-08-12       Impact factor: 3.375

5.  Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing.

Authors:  Alison B Edelman; Ganesh Cherala; Steven W Blue; David W Erikson; Jeffrey T Jensen
Journal:  Contraception       Date:  2016-03-18       Impact factor: 3.375

6.  In vitro assessment of some sperm function following exposure to levonorgestrel in human fallopian tubes.

Authors:  Alexia Hermanny; M Valeria Bahamondes; Francisco Fazano; Nadia M Marchi; Maria Elena Ortiz; Maria Heloisa R R Genghini; Horacio B Croxatto; Luis Bahamondes
Journal:  Reprod Biol Endocrinol       Date:  2012-01-30       Impact factor: 5.211

7.  A Randomized, Controlled Trial of Levonorgestrel Vs. The Yuzpe Regimen as Emergency Contraception Method among Iranian Women.

Authors:  Fatemeh Sadat Hoseini; Mohammad Eslami; Mohammed Abbasi; Fatemeh Noroozi Fashkhami; Soheila Besharati
Journal:  Iran J Public Health       Date:  2013-10       Impact factor: 1.429

8.  Association between levonorgestrel emergency contraception and the risk of ectopic pregnancy: a multicenter case-control study.

Authors:  Jian Zhang; Cheng Li; Wei-Hong Zhao; Xiaowei Xi; Shu-Jun Cao; Hua Ping; Guo-Juan Qin; Linan Cheng; He-Feng Huang
Journal:  Sci Rep       Date:  2015-02-12       Impact factor: 4.379

9.  Expressions of candidate molecules in the human fallopian tube and chorionic villi of tubal pregnancy exposed to levonorgestrel emergency contraception.

Authors:  Changxiao Huang; Mei Zhang; Chunxia Meng; Wei Shi; Lulu Sun; Jian Zhang
Journal:  Reprod Biol Endocrinol       Date:  2013-05-20       Impact factor: 5.211

Review 10.  A systematic review of effectiveness and safety of different regimens of levonorgestrel oral tablets for emergency contraception.

Authors:  Mohammad Shohel; Mohammad Mahfuzur Rahman; Asif Zaman; Mir Muhammad Nasir Uddin; Md Mamun Al-Amin; Hasan Mahmud Reza
Journal:  BMC Womens Health       Date:  2014-04-04       Impact factor: 2.809

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.